Your cash under control, without spending your days on it.
Redmontis is the only financial planning tool built for biotech: runway across long R&D cycles, clinical milestones tied to cash, the French research tax credit (CIR) and use of proceeds. A single source of truth for the CEO and CFO, to decide fast and answer the board without reopening a spreadsheet.
Built for biotech CEOs and CFOs.
Interface preview, demonstration data. See the 7 screens →
I move from an operational assumption to a strategic decision. I simulate the impact of a trial delay on our runway and walk into the board with clear, defensible scenarios.
Grégoire Serra · Chairman & CEO of Dolinnov
As a CFO, I used to spend 48 to 72 hours rebuilding Excel models before every board. With Redmontis: 2 hours, and a reliable runway without starting from a blank page.
Jonathan Susini · former CFO, Scarcell Therapeutics
Too many hours lost on spreadsheets, at the wrong moment.
You should be advancing the science and securing funding. Instead, every board, every investor question reopens an Excel file that you're the only one to understand.
+9 pts
+4 pts
4 to 6 weeks per board
Rebuilding the model and preparing the reporting before every quarterly board, on your time as an executive.
Limited responsiveness
"How much runway do we have left?" The answer requires a calculation, not a glance.
Three definitions of runway
The CEO, the CFO and the investor often don't have the same number around the table.
Sources: Panorama France HealthTech 2026 (France Biotech, February 2026, 454 to 480 respondents depending on the question).
Time reclaimed, decisions made with more confidence.
The 3-hour turnaround and the 4-to-6-week manual rebuild: feedback from CEO and CFO users.
Know where you stand, without opening a file.
Runway, burn and cash are right there, up to date. You adjust an assumption, the impact recalculates. You steer your cash instead of being driven by it, and you stay focused on the science and the raise.
See the features
Walk into meetings with ready, defensible numbers.
When an investor asks about the impact of a trial delay or a hire, you show the scenario on screen. A clear format, consistent from one meeting to the next, that builds trust without costing you a night of prep.
Request a demoDo you support biotechs? Redmontis saves you time too.
Funds, competitiveness clusters, incubators, chartered accountants: when your biotechs speak the same financial language, calculate and visualize runway and cash the same way, and present the same Use of Proceeds, everyone moves faster.
Funds & investors
Compare the runway of all your portfolio companies on the same definition and the same assumptions, and spot a cash risk months before it blows up. A holding lost to a poorly anticipated runway costs several million, while the Redmontis tool costs 18 000 € per year.
Competitiveness clusters
Your members put together public funding applications (Bpifrance, France 2030) with a coherent, traceable cash plan that stands up better in committee. You raise the financial standard across the whole ecosystem.
Incubators & accelerators
A new CEO with a scientific background gets a grip on their financial data faster: accelerated onboarding, good discipline from the start. And an investor-ready file in days, not weeks, which improves the fundraising success rate of your spin-offs.
Chartered accountants
Your clients arrive with structured data and a CIR that is already framed and sourced (article 244 quater B of the CGI, BOFiP). Fewer hours spent fixing files, and you set a standard.
The shared benefit: the same language and the same data from one company to the next, time saved for your teams, who focus on execution rather than rebuilding spreadsheets.
From 18 000 € per year.
Pricing based on capital under management. All of Redmontis, with no options or surprises. The time reclaimed and the peace of mind in meetings are well worth the spend — judge for yourself on a demo.
See pricing Request a demo